PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Reinkemeyer, C.* ; Khazaei, H.* ; Weigert, M.* ; Hannes, M.* ; Le Gleut, R. ; Plank, M.* ; Winter, S.* ; Noreña, I.* ; Meier, T.* ; Xu, L.* ; Rubio-Acero, R.* ; Wiegrebe, S.* ; Le Thi, T.G.* ; Fuchs, C. ; Radon, K.* ; Paunovic, I.* ; Janke, C.* ; Wieser, A.* ; Küchenhoff, H.* ; Hoelscher, M.* ; Castelletti, N.

The prospective COVID-19 post-immunization serological cohort in Munich (KoCo-Impf): Risk factors and determinants of immune response in healthcare workers.

Viruses 15:25 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Antibody studies analyze immune responses to SARS-CoV-2 vaccination and infection, which is crucial for selecting vaccination strategies. In the KoCo-Impf study, conducted between 16 June and 16 December 2021, 6088 participants aged 18 and above from Munich were recruited to monitor antibodies, particularly in healthcare workers (HCWs) at higher risk of infection. Roche Elecsys® Anti-SARS-CoV-2 assays on dried blood spots were used to detect prior infections (anti-Nucleocapsid antibodies) and to indicate combinations of vaccinations/infections (anti-Spike antibodies). The anti-Spike seroprevalence was 94.7%, whereas, for anti-Nucleocapsid, it was only 6.9%. HCW status and contact with SARS-CoV-2-positive individuals were identified as infection risk factors, while vaccination and current smoking were associated with reduced risk. Older age correlated with higher anti-Nucleocapsid antibody levels, while vaccination and current smoking decreased the response. Vaccination alone or combined with infection led to higher anti-Spike antibody levels. Increasing time since the second vaccination, advancing age, and current smoking reduced the anti-Spike response. The cumulative number of cases in Munich affected the anti-Spike response over time but had no impact on anti-Nucleocapsid antibody development/seropositivity. Due to the significantly higher infection risk faced by HCWs and the limited number of significant risk factors, it is suggested that all HCWs require protection regardless of individual traits.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
4.700
0.000
1
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Covid-19 ; Orchestra ; Sars-cov-2 ; Antibodies ; Breakthrough Infections ; Health Care Workers ; Immunologic Response ; Seroprevalence ; Vaccination
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 1999-4915
e-ISSN 1999-4915
Zeitschrift Viruses
Quellenangaben Band: 15, Heft: 7, Seiten: , Artikelnummer: 25 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)
Institute of Computational Biology (ICB)
CF Statistical Consulting (CF-STATCON)
POF Topic(s) 30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
30505 - New Technologies for Biomedical Discoveries
Forschungsfeld(er) Radiation Sciences
Enabling and Novel Technologies
PSP-Element(e) G-501391-001
G-503800-001
A-632200-001
Förderungen European Union
DOI 10.3390/v15071574
WOS ID 001038887600001
Scopus ID 85165941131
PubMed ID 37515259
Erfassungsdatum 2023-10-06
[➜Korrektur melden]